NeuroXess announced that it has been included in MIT Technology Review’s list of the world’s 50 smartest companies – the TR50 list – released on July 29 in Wuxi, China. NeuoXess was recognized mainly for its silk-enabled minimally invasive implantable high-throughput flexible brain-computer interface (BCI) system. It is the youngest company to date to make the list. Dr. Tiger Tao, Co-founder and Chief Scientist at NeuroXess, attended the award ceremony.
Every year since 2010, MIT Technology Review has assembled a list of what it considers the world’s 50 smartest companies, based on two necessary criteria, technology leadership and business acumen, as part of an effort to give an indication of what the future of technology will look like. Phoenix Peng, Co-founder and CEO of NeuroXess, was invited to the forum “The Power of Life Technology to Change the Future” in the afternoon, discussing the power of life technology which influences life and the future with guests.
Founded in October 2021, NeuroXess is the first high-tech life science company in China that focuses on flexible BCI technologies to protect and better understand the brain. The company has put together an outstanding team from both academia and industry to simultaneously achieve the benefits of cutting-edge research and commercialization.
Notably, at the beginning of 2022, just three months after its establishment, NeuroXess received nearly 100 million RMB of financing. This is the largest early-stage financing in the field of BCI in China. Dr. Tiger Tao has expressed confidently that, as the most representative company in the field of domestic invasive brain-computer interface, NeuroXess will rival Elon Musk’s Neuralink, its global competitor.
The silk-enabled minimally invasive implantable high-throughput flexible brain-computer interface (BCI) system has been applied and tested comprehensively in various animal models including rats, rabbits, and monkeys.
A single silk-based flexible neural probe consists of thousands of channels for single neuron recording and brain stimulation while the implantation incision is less than 0.7 mm in diameter and the in vivo time more than 8 months. Up to now, NeuroXess has completed thousands of pre-clinical animal experiments, being the first Chinese company to receive clinical ethics approval for its flexible BCI technology to go to clinical trial. It may become the world’s first choice for implantable flexible brain-computer interface solutions.
The brain-computer interface technology submission garnered the Super AI Leader, the highest award given at the 2021 World Artificial Intelligence Conference. The technology was selected as one of the conference’s key new findings together with the Huawei Pangu Large Model technology and Alibaba Cloud’s Aurora Heterogeneous Computing Acceleration Platform. The technology is also included on the list of the 2021 AI research achievements at the Chinese Academy of Sciences.
NeuroXess has achieved several core technology breakthroughs in terms of the manufacturing of the key device for the invasive brain-computer interface. Some of NeuroXess’s devices have already surpassed Neuralink in terms of certain performance indicators.
发表回复